Phase 3 N=211 Methadone Maintenance for Prisoners
Heroin Addiction
Primary: Treatment Retention in the Community — 23.1; 91.3; 166.0 Days in community treatment
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=235 Polidocanol Endovenous Microfoam (PEM) Versus Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
Varicose Veins
Primary: Change in Patient-Reported Symptoms of Varicose Veins (VVSymQ Score) — -2.00; -5.34; -6.01; -5.06 units on a scale — p=<0.0001
Phase 3 N=30 An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome
Cushing's Syndrome
Primary: Number of Participants With Adverse Events — 30 participants
Phase 3 N=527 Phase 3 Study of Sofosbuvir and Ribavirin
Hepatitis C
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After Stopping All Study Drugs (SVR12) — 67; 67 percentage of participants
Phase 3 N=263 Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Infanrix®Hexa in Healthy Peruvian Infants
Diphtheria · Tetanus · Pertussis
Primary: Number of Participants Achieving Seroprotection for Anti Hep-B After a Primary Series of Vaccination With Either DTaP-IPV-Hep B-PRP~T or Infanrix Hexa™ — 131; 130…
Phase 3 N=31 Savella in Treatment for Provoked Vestibulodynia
Vestibulodynia · Vulvodynia
Primary: Pain Rating Index — 12.3 units on a scale — p=.001
Phase 3 N=361 Study of Participants With Advanced Non-Small Cell Lung Cancer
Advanced Non-Small Cell Lung Cancer
Primary: Progression Free Survival Without Grade 4 Toxicity (G4PFS) as Measured by the Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 — 3.91; 2.86 months…
Phase 3 N=535 Open-label Safety Extension Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults
Major Depressive Disorder
Primary: Number of Patients With Adverse Events (AEs) — 391; 18; 42 participants
Phase 3 N=356 CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a)
Lymphocytic Leukemia, Chronic
Primary: Progression-free Survival (PFS) — 31.1; 11.1 Months — p=<0.0001
Phase 3 N=412 Comparison of a DTaP-IPV-HB-PRP~T Combined Vaccine to Infanrix™-Hexa, When Administered With Prevnar® in Thai Infants
Hepatitis B · Polio · Diphtheria
Primary: Number of Participants Achieving Seroprotection Against Hepatitis B and Haemophilus Influenzae Type b Post-vaccination With Either DTaP-IPV-Hep B-PRP~T + Prevnar™ or…
Phase 3 N=892 A Study in Relapse Prevention of Treatment-Resistant Depression
Treatment Resistant Depression
Primary: Time to Relapse by Any Criteria — NA; NA days — p=<0.001
Phase 3 N=122 VEGF Trap-Eye in Choroidal Neovascularization Secondary to Pathologic Myopia (mCNV)
Myopia, Pathological
Primary: Mean Change in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) From Baseline to Week 24 - Last Observation Carried…
Phase 3 N=307 Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatate in the Treatment of Asthma in Adolescent and Adult Subjects of Asian Ancestry.
Asthma
Primary: Mean Change From Baseline (BL) in Daily Evening (PM) Peak Expiratory Flow (PEF) Averaged Over the 12-week Treatment Period — -11.8; 39.2 Liters/minute (L/min) — p=<0.001
Phase 3 N=100 Dexmedetomidine Versus Fentanyl Following Pressure Equalization Tube Placement
Chronic Otitis Media
Primary: FLACC Behavioral Pain Assessment Scale Scores — 5; 3; 1; 2 units on a scale
Phase 3 N=817 Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression
Bipolar Depression
Primary: Number of Participants With Serious and Non-serious Treatment-emergent Adverse Events Who Have Completed 24 Weeks of Extension Study Treatment — 529 participants